Dean Y Li Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Dean Y Li is Director of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 75,703 shares of RXRX, which is worth approximately $559,445. The most recent transaction as insider was on Oct 01, 2024, when has been sold 1,925 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 75.7K

2.61% 3M change

94.29% 12M change

Total Value Held $559,445

Dean Y Li Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 01 2024	BUY Grant, award, or other acquisition	-	1,925 Added 2.48%	75,703 Class A Common Stock
Jul 01 2024	BUY Grant, award, or other acquisition	-	1,592 Added 2.11%	73,778 Class A Common Stock
Jun 03 2024	BUY Grant, award, or other acquisition	-	13,097 Added 15.36%	72,186 Class A Common Stock
Apr 01 2024	BUY Grant, award, or other acquisition	-	1,267 Added 2.1%	59,089 Class A Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	1,203 Added 0.09%	1,327,618 Class A Common Stock
Oct 02 2023	BUY Grant, award, or other acquisition	-	1,659 Added 0.12%	1,326,415 Class A Common Stock
Jul 03 2023	BUY Grant, award, or other acquisition	-	1,609 Added 0.25%	637,461 Class A Common Stock
Jun 16 2023	BUY Grant, award, or other acquisition	-	12,612 Added 1.94%	636,021 Class A Common Stock
Apr 03 2023	BUY Grant, award, or other acquisition	-	1,724 Added 0.28%	623,409 Class A Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	1,573 Added 0.25%	621,685 Class A Common Stock
Oct 03 2022	BUY Grant, award, or other acquisition	-	1,092 Added 0.18%	620,112 Class A Common Stock
Jul 01 2022	BUY Grant, award, or other acquisition	-	1,409 Added 0.23%	619,020 Class A Common Stock
Jun 14 2022	BUY Grant, award, or other acquisition	-	18,145 Added 2.85%	617,611 Class A Common Stock
Apr 01 2022	BUY Grant, award, or other acquisition	-	1,544 Added 0.26%	599,466 Class A Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	659 Added 0.11%	597,922 Class A Common Stock
Nov 19 2021	SELL Open market or private sale	$272,175 $20.2 p/Share	13,474 Reduced 2.28%	578,163 Class A Common Stock
Nov 17 2021	SELL Open market or private sale	$112,745 $20.04 p/Share	5,626 Reduced 0.94%	591,637 Class A Common Stock
Oct 01 2021	BUY Grant, award, or other acquisition	-	543 Added 0.09%	597,263 Class A Common Stock
Jul 01 2021	BUY Grant, award, or other acquisition	-	330 Added 0.06%	596,720 Class A Common Stock
Apr 20 2021	SELL Other acquisition or disposition	-	596,390 Reduced 100.0%	0 Common Stock
Apr 20 2021	BUY Other acquisition or disposition	-	596,390 Added 50.0%	596,390 Class A Common Stock
Apr 16 2021	BUY Grant, award, or other acquisition	-	13,889 Added 2.28%	596,390 Common Stock

Also insider at

MRK

Merck & Co., Inc. Healthcare

Executive VP & President, MRL

DYL

Dean Y Li

Director

Kenilworth, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account